Cuesta-Mateos et al. [37] demonstrated that anti-CCR7 monoclonal antibodies can preserve T cell subsets while effectively removing tumor cells through a complement-mediated mechanism of action in chronic lymphocytic leukemia (CLL). This evidence concerns the gene CCR7 and neoplasm.